Premium
Early recognition of ipilimumab‐related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management
Author(s) -
Tiu Crescens,
Pezaro Carmel,
Davis Ian D,
Grossmann Mathis,
Parente Phillip
Publication year - 2015
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12348
Subject(s) - ipilimumab , medicine , hypophysitis , melanoma , adverse effect , monoclonal antibody , ctla 4 , immunology , immunotherapy , complication , immune system , oncology , antibody , t cell , cancer research , pituitary gland , hormone
Ipilimumab is a human anti‐ CTLA ‐4 monoclonal antibody recently approved for the treatment of advanced melanoma. Stimulation of T ‐cell activity unmasks antitumor activity, but can cause immune‐related adverse events. Autoimmune hypophysitis is of particular importance because its presentation can be subtle but life threatening. We present two cases where early recognition of ipilimumab‐related autoimmune hypophysitis led to timely intervention and low subsequent morbidity, without compromise of antitumor effects. We provide recommendations for detection and management of this potentially life‐threatening complication of ipilimumab.